Lombaard J, Ssali F, Thanyawee P, Fourie J, Vanveggel S, Linthicum C
Antimicrob Agents Chemother. 2021; 66(2):e0091621.
PMID: 34871089
PMC: 8846324.
DOI: 10.1128/AAC.00916-21.
Meloni S, Onwuamah C, Agbaji O, Chaplin B, Olaleye D, Audu R
Open Forum Infect Dis. 2017; 4(4):ofx233.
PMID: 29255731
PMC: 5726477.
DOI: 10.1093/ofid/ofx233.
Meloni S, Chaplin B, Idoko J, Agbaji O, Akanmu S, Imade G
AIDS Res Ther. 2017; 14(1):58.
PMID: 29029637
PMC: 5640939.
DOI: 10.1186/s12981-017-0184-5.
Sepulveda-Torres L, Rishishwar L, Rogers M, Rios-Olivares E, Boukli N, Jordan I
PLoS One. 2017; 12(5):e0177452.
PMID: 28493944
PMC: 5426751.
DOI: 10.1371/journal.pone.0177452.
Ramadhani H, Muiruri C, Maro V, Nyombi B, Omondi M, Mushi J
AIDS Behav. 2017; 22(5):1671-1678.
PMID: 28185021
PMC: 5550377.
DOI: 10.1007/s10461-017-1721-x.
Preconception care: preventing and treating infections.
Lassi Z, Imam A, Dean S, Bhutta Z
Reprod Health. 2014; 11 Suppl 3:S4.
PMID: 25415557
PMC: 4196562.
DOI: 10.1186/1742-4755-11-S3-S4.
Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Chen J, Liang Z, Wang W, Yi C, Zhang S, Zhang Q
Sci Rep. 2014; 4:6872.
PMID: 25362963
PMC: 4217091.
DOI: 10.1038/srep06872.
The HIVToolbox 2 web system integrates sequence, structure, function and mutation analysis.
Sargeant D, Deverasetty S, Strong C, Alaniz I, Bartlett A, Brandon N
PLoS One. 2014; 9(6):e98810.
PMID: 24886930
PMC: 4041786.
DOI: 10.1371/journal.pone.0098810.
Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
Zheng Y, Hughes M, Lockman S, Benson C, Hosseinipour M, Campbell T
Clin Infect Dis. 2014; 59(6):888-96.
PMID: 24842909
PMC: 4155445.
DOI: 10.1093/cid/ciu367.
Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolates.
Jang D, Yoon C, Choi B, Chung Y, Kim H, Chi S
J Korean Med Sci. 2014; 29(3):456-9.
PMID: 24616600
PMC: 3945146.
DOI: 10.3346/jkms.2014.29.3.456.
Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data.
van Westen G, Hendriks A, Wegner J, IJzerman A, van Vlijmen H, Bender A
PLoS Comput Biol. 2013; 9(2):e1002899.
PMID: 23436985
PMC: 3578754.
DOI: 10.1371/journal.pcbi.1002899.
Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.
Jiao L, Li H, Li L, Zhuang D, Liu Y, Bao Z
AIDS Res Treat. 2012; 2012:637263.
PMID: 22536497
PMC: 3318213.
DOI: 10.1155/2012/637263.
Anti-human immunodeficiency virus type 1 activity of novel 6-substituted 1-benzyl-3-(3,5-dimethylbenzyl)uracil derivatives.
Ordonez P, Hamasaki T, Isono Y, Sakakibara N, Ikejiri M, Maruyama T
Antimicrob Agents Chemother. 2012; 56(5):2581-9.
PMID: 22290950
PMC: 3346622.
DOI: 10.1128/AAC.06307-11.
Estimating the individualized HIV-1 genetic barrier to resistance using a nelfinavir fitness landscape.
Theys K, Deforche K, Beheydt G, Moreau Y, Van Laethem K, Lemey P
BMC Bioinformatics. 2010; 11:409.
PMID: 20682040
PMC: 2921410.
DOI: 10.1186/1471-2105-11-409.
Synthesis and Anti-HIV-1 Activity of a Novel Series of Aminoimidazole Analogs.
Ganguly S, Murugesan S, Prasanthi N, Alpturk O, Herman B, Sluis-Cremer N
Lett Drug Des Discov. 2010; 7(5):318-323.
PMID: 20535242
PMC: 2882308.
DOI: 10.2174/157018010791163424.
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
Halvas E, Wiegand A, Boltz V, Kearney M, Nissley D, Wantman M
J Infect Dis. 2010; 201(5):672-80.
PMID: 20102272
PMC: 2835354.
DOI: 10.1086/650542.
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S, Torti C, Prosperi M, Manca N, Lapadula G, Paraninfo G
Infection. 2009; 37(5):438-44.
PMID: 19669091
DOI: 10.1007/s15010-009-8237-x.
Host sequence motifs shared by HIV predict response to antiretroviral therapy.
Dampier W, Evans P, Ungar L, Tozeren A
BMC Med Genomics. 2009; 2:47.
PMID: 19627600
PMC: 2723131.
DOI: 10.1186/1755-8794-2-47.
TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories.
Land S, Cunningham P, Zhou J, Frost K, Katzenstein D, Kantor R
J Virol Methods. 2009; 159(2):185-93.
PMID: 19490972
PMC: 2863146.
DOI: 10.1016/j.jviromet.2009.03.016.
Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.
Tossonian H, Raffa J, Grebely J, Viljoen M, Mead A, Khara M
Open Virol J. 2009; 1:8-13.
PMID: 19440454
PMC: 2675547.
DOI: 10.2174/1874357900701010008.